Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
OPERATING EXPENSES:
Research and development	$ 19,035	$ 15,362
General and administrative	12,753	10,058
Total operating expenses	31,788	25,420
LOSS FROM OPERATIONS:	(31,788)	(25,420)
OTHER INCOME, NET:
Other income, net	709	134
Foreign exchange gains	2,685	1,333
Benefit from R&D tax credit	4,316	2,922
Total other income, net	7,710	4,389
Loss before income taxes	(24,078)	(21,031)
Income tax expense	(130)	(140)
Net loss	(24,208)	(21,171)
Other comprehensive loss:
Foreign exchange translation adjustment	(578)	(7,193)
Comprehensive loss	$ (24,786)	$ (28,364)
Net loss per share - basic (in dollars per share)	$ (0.57)	$ (0.50)
Net loss per share - diluted (in dollars per share)	$ (0.57)	$ (0.50)
Weighted average ordinary shares outstanding - basic (in shares)	42,725,863	42,036,563
Weighted average ordinary shares outstanding - diluted (in shares)	42,725,863	42,036,563